MedTrace Logo

Effect of Cannabinoid (THC / CBD 50%) on Hyperalgesia in Patients With Deep Endometriosis

NCT03875261 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2019-03-14

No results posted yet for this study

Summary

This study evaluates the treatment of the symptoms of deep endometriosis with a cannabinoid derivate.

Conditions

  • Endometriosis

Interventions

DRUG

Cannabinoid treatment

Participants are treated with cannabinoid derivates with a dose between 1 to 12 puffs, each puffs contains 2,7 mg of delta-9-tetrahidrocannabinol and 2,5 mg of cannabidiol.

Sponsors & Collaborators

  • Fundació Clínic per la Recerca Biomedica

    collaborator UNKNOWN

  • Dr. Christian Dursteler

    collaborator UNKNOWN

  • David Garcia Cinca

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-04-01
Primary Completion
2019-07-15
Completion
2019-07-15

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03875261 on ClinicalTrials.gov